Prevention and treatment of cancer using so-called medicinal mushrooms raw materials: Criticism, facts, and perspectives


The purpose of the present review is the analysis of modern knowledge on use of “medicinal mushrooms” metabolites in cancer treatment, including in vitro experiments and clinical studies, with a preliminary assessment of the prospects for the development at least of some tactics of immunotherapy for malignant neoplasms. The data on the efficacy of adjuvant therapy of tumors in combination with mushroom extracts in relation to tumor regression as well as improving overall survival rates are presented. It is postulated that the improvement of long-term results of treatment can be most successfully reached with the use of “medicinal mushrooms” raw materials. This is due to the fact that an important task after adjuvant therapy (i.e. enhancing the immune surveillance of tumor derivatives) can be successfully solved using polysaccharides of fungal origin. In their final links and targets, such a practice coincides with clinically proven cytokine therapy. The involvement of Russian clinicians in practice of assessment of long-term results of treatment with fungal dectin-stimulation seems to us to be important task of clinical oncology.

About the authors

Ivan V. Zmitrovich

Komarov Botanical Institute of the Russian Academy of Sciences, St. Petersburg, Russia

Author for correspondence.
ORCID iD: 0000-0002-3927-2527

Russian Federation, 197376, St. Petersburg, Professor Popov str., 2

D.Sc. in Biology, Leading Researcher, Laboratory of Systematics and Geography of the Fungi

Vyacheslav A. Vlasenko

Central Siberian Botanical Garden SB RAS, Novosibirsk, Russia


Russian Federation, 101 Zolotodolinskaya str., Novosibirsk, 630090, Russia

Ph.D. in Biology, Senior Researcher, Laboratory of Lower Plants

Vladimir V. Perelygin

Saint-Petersburg State and Chemical Pharmaceutical University, Saint-Petersburg, Russia

ORCID iD: 0000-0002-0999-5644
SPIN-code: 3128-7451
ResearcherId: AAV-6556-2020

Russian Federation, 197376, Russia, St. Petersburg, Professor Popov str., 14, letter A;

Doctor  of  Medicine (MD),  Professor,  Head  of  the  Industrial Ecology Department

Igor S. Figurin

Saint-Petersburg Medico-Social Institute, Saint Petersburg, Russia


Russian Federation, 195271, Russia, St. Petersburg, Kondratyevsky Prospekt, 72 letter " A»

Ph.D. in Medicine, Associate Professor, Head of the Department of Infectious Diseases, Phthisiology, Dermatovenerology and Medical and Preventive Disciplines


  1. World Health Organization. Cancer. 2018.
  2. Hodge JW, Ardiani A, Farsaci B, et al. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Seminars in Oncology. 2012; 39: 323–339. doi: 10.1053/j.seminoncol.2012.02.006.
  3. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians. 2016; 66: 271–289. doi: 10.3322/caac.21349.
  4. Zmitrovich IV, Belova NV, Balandaykin ME, et al. Cancer without pharmacological illusions and a niche for mycotherapy (Review). International Journal of Medicinal Mushrooms. 2019; 21: 105–19. doi: 10.1615/IntJMedMushrooms.2019030047.
  5. Денисова, Н. П. Лечебные свойства грибов. Этномикологический очерк / Н. П. Денисова. – Санкт-Петербург: Издательство СПХФА, 1998. – 59 с.
  6. Peintner U, Pöder R, Pümpel T. The iceman’s fungi. Mycological Research. 1998; 102: 1153‒62.
  7. Lucas EH, Montesano R, Pepper MS, et al. Tumor inhibitors in Boletus edulis and other Holobasidiomycetes. Antibiotics and Chemoterapy. 1957. 7: 1–4.
  8. Gregory FJ, Healy EM, Agersborg HP, Warren GH. Studies on antitumor substances produced by Basidiomycete. Mycologia. 1966; 58: 80–90.
  9. Komatsu N, Okubo S, Kikumoto S, et al. Host-mediated antitumor action of schizophyllan, a glucan produced by Schizophyllum commune. Gann. 1969; 60(2): 133–144.
  10. Ikekawa T, Ikeda Y, Yoshioka Y, et al. Antitumor polysaccharides of Flammulina velutipes 2. The structure of EA-3 and further purification of EA-5. Journal of Pharmacobio-Dynamics. 1982; 5: 576–81.
  11. Ikekawa T, Saitoh H, Feng W, et al. Antitumor activity of extracts and polysaccharides. Chemical and Pharmaceutical Bulletin (Tokyo). 1992; 40: 1954–57.
  12. Ikekawa T, Uehara N, Maeda Y, et al. Antitumor activity of aqueous extracts of edible mushrooms. Cancer Research. 1969; 29: 734–35.
  13. Mizuno T. Development of antitumor polysaccharides from mushroom fungi. Foods and Food Ingredients Journal of Japan. 1996; 167: 69–85.
  14. Mizuno T, Ando M, Sugie R, et al. Antitumor activity of some polysaccharides isolated from an edible mushroom, ningyotake, the fruiting body and the cultured mycelium of Polyporus confluens. Bioscience, Biotechnology, and Biochemistry. 1992; 56: 34–41.
  15. Mizuno T, Morimoto M, Minato KI, et al. Polysaccharides from Agaricus blazei stimulate lymphocyte T-cell subsets in mice. Bioscience, Biotechnology, and Biochemistry. 1998; 62: 434–37.
  16. Mizuno T, Ohsawa K, Hagiwara N, et al. Fractionation and characterization of antitumor polysaccharides from Maitake, Grifola frondosa. Agricultural and Biological Chemistry. 1986; 50: 1679–88.
  17. Mizuno T, Yeohlui P, Kinoshita T, et al. Antitumor activity and chemical modification of polysaccharides from Niohshimeji mushroom, Tricholoma giganteum. Bioscience, Biotechnology, and Biochemistry. 1996; 60: 30–33.
  18. Mizuno T, Zhuang C, Abe K, et al. Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetidae). International Journal of Medicinal Mushrooms. 1999; 1: 301–316.
  19. Chichara G, Hamuro J, Maeda YY, Arai Y, Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes. Cancer Research. 1970; 30: 2776–81.
  20. Tsukagoshi S, Hashimoto Y, Fujii G, et al. Krestin (PSK). Cancer Treatment Reviews. 1984; 11: 31–55.
  21. Brown GD, Gordon S. Immune recognition: a new receptor for β-glucans. Nature. 2001; 413: 36–37. doi: 10.1038/35092620.
  22. Булатов, П. К., Березина, М. П., Якимов, П. А. (ред.) Чага и ее лечебное применение при раке IV стадии / П. К. Булатов [и др.]. – Ленинград: Медгиз, 1959. – 305 с.
  23. Змитрович, И. В., Денисова, Н. П., Баландайкин, М. Э. [и др.] Чага и ее биоактивные комплексы: история и перспективы / И. В. Змитрович [и др.] // Формулы Фармации. – 2020. – Т. 2. – № 2. – С. 84–93. doi: 10.17816/phf34803/2713-153X-2020-2-2-84-93.
  24. Jin X, Ruiz Beguerier J, Sze DM, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatement. Cochrane Database of Systematic Reviews. 2012. 6: CD007731. doi: 10.1002/14651858.CD007731.pub2.
  25. Money NP. Are mushrooms medicinal? Fungal Biology. 2016. 129(4): 449–453. doi: 10.1016/j.funbio.2016.01.006.
  26. Большаков, С. Здравствуйте, я рейши, я же линчжи, и я супергриб / C. Большаков // Вести микологии. – 2020. –
  27. Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database of Systematic Reviews. 2015; CD007259. DOI:
  28. Reishi Mushroom. In: Memorial Sloan Kettering Cancer Center. For adult patients. Accessed 12.11.2020.
  29. Chmielowski B, Territo M. Manual of clinical oncology. Philadelphia: Lippincott Williams and Wilkins (LWW), 2017. eBook.
  30. Chu E, DeVita VT. Physicians’ cancer chemotherapy drug manual. Amsterdam etc.: Elsevier; 2020.
  31. Zhong L, Yan P, Lam WC, et al. Coriolus versicolor and Ganoderma lucidum related natural products as an adjunct therapy for cancers: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2019. Online article. doi: 10.3389/fphar.2019.00703.
  32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Annals of Internal Medicine. 2009; 151: 264–269. doi: 10.7326/0003-4819-151-4-200908180-00135.
  33. Higgins JPT et al. (eds). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011. London: the cochrane collaboration, 2011.
  34. Swaminathan R, Brenner H. Stastistical methods for cancer survival analysis. IARC Scientific Publications. 2011; 162: 7‒13.
  35. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle. 2006; 5: 1744‒1750. doi: 10.4161/cc.5.16.2864.
  36. Higham E, Wittrup KD, Chen J. Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. Journal of Immunology. 2010; 184(7): 3394–400. doi: 10.4049/jimmunol.0903111.
  37. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis Lancet. 2002; 360(9340): 1131–35. doi: 10.1016/S0140-6736(02)11199-8.
  38. Rich R (ed.) Clinical immunology. Principles and Practice (Third Edition). Mosby; 2008.
  39. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urologic Oncology. 2001; 19(2): 148–54.
  40. Илюшин, А. Л., Красная, Я. Л., Шабалкин, П. И. Результаты открытого сравнительного исследования в параллельных группах по оценке эффективности и безопасности лекарственного препарата Рефнот® (фактор некроза опухолей – тимозин-1 альфа рекомбинантный) в лечении диссеминированного тройного негативного рака молочной железы / А. Л. Илюшин [и др.] // Медицина. – 2019. – Т. 7. – № 3. – 138–149. doi: 10.29234/2308-9113-2019-7-3-138-149.
  41. Brown GD, Herre J, Williams DL. Dectin-1 mediates the biological effects of beta-glucans. Journal of Experimental Medicine. 2003; 197(9): 1119–24. doi: 10.1084/jem.20021890.
  42. Gantner BN, Simmons RM, Canavera SJ, et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. Journal of Experimental Medicine. 2003; 197(9): 1107–1117. doi: 10.1084/jem.20021787.
  43. Gross O, Gewies A, Finger K, et al. Card9 controls a non-TLR signaling pathway for innate anti-fungal immunity. Nature. 2006; 442(7103): 651–56.
  44. Ikeda Y, Adachi Y, Ishii T, et al. Dissociation of Toll-like receptor 2-mediated innate immune response to zymosan by organic solvent-treatment without loss of Dectin-1 reactivity. Biological and Pharmaceutical Bulletin. 2008; 31(1): 13–18.
  45. Dennehy KM, Brown GD. The role of the β-glucan receptor Dectin-1 in control of fungal infection. J Leukoc Biol. 2007;82(2):253–58.
  46. Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Frontiers in Immunology. 2015; 6: 569. doi: 10.3389/fimmu.2015.00569.
  47. Jiang J, Slivova V, Valachovicova T, et al. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. International Journal of Oncology. 2004; 24: 1093–1099. doi: 10.3892/ijo.24.5.1093.
  48. Xia Q, Zhang H, Sun X, et al. A comprehensive review of the structure elucidation and biological activity of triterpenoids from Ganoderma spp. Molecules. 2014; 19: 17478–17535.
  49. Wagner EF, Nebreda ÁR. Signal integration by JNK and p39 MAPK pathways in cancer development. Nature Reviews Cancer. 2009; 9: 537–549. doi: 10.1038/nrc2694.
  50. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002; 25: 511–18. doi: 10.1159/000068621.
  51. Chan GCF, Chan WK, Sze DMY. The effects of β-glucan on human immune and cancer cells. Journal of Hematology and Oncology. 2009; 2: 25. doi: 10.1186/1756-8722-2-25.
  52. Hyde KD, Xu J, Rapior S, et al. The amazing potential of fungi: 50 ways we can exploit fungi industrially. Fungal Diversity. 2019; 97: 1–136. doi: 10.1007/s13225-019-00430-9.
  53. Furtado C, Pirson L, Edelberg H, et al. Pentacyclic triterpene bioavailability: An overview of in vitro and in vivo studies. Molecules. 2017; 22: 1–400. doi: 10.3390/molecules22030400.
  54. Balandaykin ME, Zmitrovich IV. Review on Chaga medicinal mushroom, Inonotus obliquus (higher Basidiomycetes): realm of medicinal applications and approaches on estimating its resource potential. International Journal of Medicinal Mushrooms. 2015; 17(2): 95–104. doi: 10.1615/intjmedmushrooms.v17.i2.10.
  55. Dinesh C, Agrawal MD (eds.). Medicinal mushrooms: Recent progress in research and development. Springer; 2019. eBook.
  56. Erkel G, Anke T, Sterner O. Inhibition of NF-kappa B activation by panepoxydone. Biochemical and Biophysical Research Communications. 1996; 226(1): 214–21.
  57. Zmitrovich IV, Arefyev SP, Bondartseva MA, et al. Professor Shu-Ting Chang, cancer mycotherapy and Le Chatelier principle. International Journal of Medicinal Mushrooms. 2020; 22(9): 835–844. doi: 10.1615/IntJMedMushrooms.2020035862.
  58. Zmitrovich IV, Bondartseva MA, Arefyev SP, et al. Profiles of little-known medicinal polypores: Funalia trogii (Agaricomycetes). International Journal of Medicinal Mushrooms. 2018; 20(7): 657–64. doi: 10.1615/IntJMedMushrooms.2018026564.
  59. Шашкина, М. Я., Сергеев, А. В. Фитодраже «Чаговит» / М. Я. Шашкина, A. В. Сергеев. – 2003. – НТД. Рег. уд. МЗ РФ № 005871. – Р.643.07.2003.
  60. Шашкина, М. Я., Сергеев, А. В. Сухой фитоэлексир «Чаговит» / М. Я. Шашкина, A. В. Сергеев. – 2003. – НТД. Рег. уд. МЗ РФ №005878. – Р.643.07.2003.
  61. Сергеев, А. В., Шашкина, М. Я. Итоги и перспективы создания средств химиопрофилактики рака / А. В. Сергеев, М. Я. Шашкина // Российский биотерапевтический журнал. – 2006. – № 3. – Т. 5. – С. 106–114.
  62. Шашкина, М. Я., Шашкин, П. Н., Сергеев, А. В. Чага в онкологии / М. Я. Шашкина [и др.] // Российский биотерапевтический журнал. – 2005. – № 4. – Т. 4. – С. 59–71.



Abstract - 140

PDF (Russian) - 2


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 2020 Pharmacy Formulas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies